We examine key genomic mutations (e.g., TP53, chromosomal instability), metabolic reprogramming (including glycolysis, glutaminolysis, and lipid metabolism), and their interplay with the tumor microenvironment (TME). The gene discussed is TP53; the disease is neoplasm.